I think if Amarin decided to sell for $15, there would be BPs lined up for the company if you factor in ANCHOR. That would be selling for a little over $2 billion, which is a lot but considering Lovaza produces over a billion a year, it's really not. ANCHOR is the key which should really increase a BO price, in addition to maybe being the trigger for NCE acceptance. I will definitely be curious what the pps at the end of the year. Until AMRN gets the ANCHOR approval, big investment firms are going to be dumping their money in other stocks. Once we get the ANCHOR approval, the money and interest should definitely coming rolling back in along with speculation for a BO.
Your arguments are poorly thought out. All they had to do was market Lovaza and they would turn a profit on their investment. period. BP has a history of watching the little guys take the risks until they have a proven product, at least in the mind of BP. That is the real base to the Feuerstein-Ratain rule as far as trial cancer drugs.
BP may have had doubts about Vascepa v. Lovaza. But now the evidence is piling up for Vascepa's benefits and Lovaza just got the warning label for Afib-ouch!
alabama two months into the launch with ok scripts numbers and plenty of catalysts on the way is hardly what I would call a catastrophe. Hang in there you obviously have done your homework judging by your previous posts far from end game.
you're right, just getting old watching continual drop. went through the same thing with NVIV, but it's finally doing what I always knew it would, heading up. be glad when FDA announces anchor PDUFA date.